Indian stocks: Visit www.stage2stocks.com →

Taysha Gene Therapies, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Taysha Gene Therapies is in Stage 4, the downtrend phase, now in week 2 (since Oct 14, 2026). It closed at $4.01, 42.6% below its 52-week high and below its 200-day average, which is falling.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic disease… More about the company

$4.01
-3.49% today
$1.3B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TSHA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 20w
S4 14w
S4 16w
S2 38w
S2 13w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 3w → S2 10w → S3 13w → S4 1w → S3 1w → S2 20w → S3 6w → S4 14w → S1 5w → S4 16w → S1 4w → S2 38w → S3 8w → S2 13w → S3 4w → S2 3w → S3 5w → S4 1w current
Total tracked: 165 weeks across 18 stage runs.

TSHA among Biotechnology255th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…255TSHAStage 4 · wk 238−18.4%
vs 52W High
-42.6%
$3.51 lo$6.98 hi
42.6% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 2
1w13w26w
Week 2, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-25.2%
200 DMA: $5.35 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.82x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.4%
3M
-27.4%
6M
-37.4%
YTD
-23.7%
1Y
-22.2%
Scan Membership
Breakout Watch
Latest: 2025-06-02
3 appearances in last 60 days. First seen: 2023-09-06.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 2 · Vol 0.82x
2026-10-21S4
Wk 2 · Vol 0.78x
2026-10-20S4
Wk 1 · Vol 2.99x
2026-10-19S4
Wk 1 · Vol 1.62x
2026-10-16S4
Wk 1 · Vol 0.77x
2026-10-15S4
Wk 1 · Vol 1.33x
2026-10-14S43→4
Wk 1 · Vol 1.24x
2026-10-13S3
Wk 5 · Vol 1.79x
2026-10-12S3
Wk 5 · Vol 1.25x
2026-10-09S3
Wk 5 · Vol 1.61x
2026-10-08S3
Wk 5 · Vol 1.18x
2026-10-07S3
Wk 5 · Vol 1.19x
Moving averages & range
50 DMA
$5.06
200 DMA
$5.35
52W High
$6.98
52W Low
$3.51
5D Low
$3.62
Resistance levels (recent highs)
20d High
$4.99
60d High
$6.68
120d High
$6.98
250d High
$6.98
Next resistance
+24.6%
to 20d High
ROE
-47.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.4

Taysha Gene Therapies: quick answers

What stage is Taysha Gene Therapies in?

As of Oct 22, 2026, Taysha Gene Therapies (TSHA) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Taysha Gene Therapies in an uptrend?

No. Taysha Gene Therapies is in a Stage 4 downtrend. It trades 25.2% below its 200-day average, which is falling.

How far is Taysha Gene Therapies from its 52-week high?

Taysha Gene Therapies closed at $4.01 on Oct 22, 2026, 42.6% below its 52-week high of $6.98. Its 52-week low is $3.51.

How has Taysha Gene Therapies performed over the past year?

As of Oct 22, 2026, Taysha Gene Therapies is down 22.2% over the past year and down 23.7% so far in 2026.

Which sector and industry is Taysha Gene Therapies in?

Taysha Gene Therapies is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.